A Randomized Controlled Trial of Autostereoscopic 3D Vision Therapy for Amblyopia
NCT: NCT07709832 · NOT_YET_RECRUITING
Brief Summary
The goal of this clinical trial is to learn if an autostereoscopic 3D amblyopia training system works to improve vision in children and adolescents with amblyopia. It will also learn about the safety and tolerability of the 3D training system. The main questions it aims to answer are: * Does autostereoscopic 3D vision training improve best corrected visual acuity in the amblyopic eye compared to conventional patching therapy? * What side effects or discomfort do participants experience during 3D training versus patching? Researchers will compare the autostereoscopic 3D training system to conventional daily eye patching to see which treatment works better for improving vision in amblyopia. Participants will: * Be randomly assigned to either the 3D training group or the patching group * Complete daily home treatment for 6 months - either 20 minutes of 3D vision training or 2 hours of continuous eye patching * Visit the clinic at baseline, 1 month, 3 months, and 6 months for eye exams and vision tests * Have their treatment progress monitored remotely through training data logs or patching diaries
Frequently Asked Questions
What is A Randomized Controlled Trial of Autostereoscopic 3D Vision Therapy for Amblyopia?
A Randomized Controlled Trial of Autostereoscopic 3D Vision Therapy for Amblyopia is a clinical trial registered under NCT07709832. Current status: NOT_YET_RECRUITING.
What is the status of NCT07709832?
The current status of NCT07709832 (A Randomized Controlled Trial of Autostereoscopic 3D Vision Therapy for Amblyopia) is: NOT_YET_RECRUITING.
When did A Randomized Controlled Trial of Autostereoscopic 3D Vision Therapy for Amblyopia start?
A Randomized Controlled Trial of Autostereoscopic 3D Vision Therapy for Amblyopia started on 2026-07-31.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.